Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Collegium Pharmaceutical (COLL) and Acorda Therapeutics (ACOR).
Collegium Pharmaceutical (COLL)
Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $35. The company’s shares closed yesterday at $13.89, close to its 52-week low of $13.10.
Folkes wrote:
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.5% and a 42.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Emergent Biosolutions, and Jazz Pharmaceuticals.
Collegium Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $33.33.
See today’s analyst top recommended stocks >>
Acorda Therapeutics (ACOR)
In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Acorda Therapeutics, with a price target of $18. The company’s shares closed yesterday at $15.56, close to its 52-week low of $12.86.
Olson noted:
“ACOR reported 4Q:18 numbers with $69.2M in revenues beating 48.1M consensus. Ampyra erosion is setting the stage for INBRIJA launch in the next few weeks at a price of $950 per pack (30 doses + inhaler), which should be sufficient for a month for most patients. Price is in line with our previous assumption, and we model a 15% GtN discount and 80% compliance, leading us to a net annual price of ~$7.5K. ACOR is leveraging past Ampyra sales experience for the INBRIJA launch and is focusing on: 1) healthcare provider engagement initially focused on high volume prescribers (~2K out of eventually ~10K HCPs), 2) patient engagement, and 3) digital promotion. Additional focus is EU partnering, possibly by YE, and pipeline execution with migraine asset.”
According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.2% and a 39.8% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Acorda Therapeutics is a Hold with an average price target of $21.83, representing a 40.3% upside. In a report issued on January 31, Cantor Fitzgerald also assigned a Hold rating to the stock with a $19 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
